Difference between revisions of "Letrozole (Femara)"
Jump to navigation
Jump to search
Warner-admin (talk | contribs) m (Text replacement - "[[Breast_cancer,_ER/PR-" to "[[Breast_cancer,_ER-") Tags: mobile edit mobile web edit |
|||
| Line 14: | Line 14: | ||
==History of changes in FDA indication== | ==History of changes in FDA indication== | ||
| − | *1/10/2001 (earliest label available at Drugs @ FDA): indicated for first-line treatment of postmenopausal women with [[ | + | *1/10/2001 (earliest label available at Drugs @ FDA): indicated for first-line treatment of postmenopausal women with [[Biomarkers#HR|hormone receptor]] [[Biomarkers#Expression|positive]] or [[Biomarkers#HR|hormone receptor]] [[Biomarkers#Unknown|unknown]] locally advanced or metastatic [[breast cancer]]. |
| + | **Femara is also indicated for the treatment of advanced [[breast cancer]] in postmenopausal women with disease progression following [[Regimen_classes#Antiestrogen_therapy|antiestrogen therapy]]. | ||
*10/29/2004: Label expanded for the extended adjuvant treatment of early breast cancer in postmenopausal women who have received 5 years of adjuvant tamoxifen therapy. ''(Indication expanded to adjuvant setting after prior therapy)'' | *10/29/2004: Label expanded for the extended adjuvant treatment of early breast cancer in postmenopausal women who have received 5 years of adjuvant tamoxifen therapy. ''(Indication expanded to adjuvant setting after prior therapy)'' | ||
| − | *12/28/2005: Label expanded for the adjuvant treatment of postmenopausal women with [[ | + | *12/28/2005: Label expanded for the adjuvant treatment of postmenopausal women with [[Biomarkers#HR|hormone receptor]] [[Biomarkers#Expression|positive]] early [[breast cancer]]. ''(Indication expanded to adjuvant setting)'' |
*3/2/2010: Label simplified to: | *3/2/2010: Label simplified to: | ||
| − | **Adjuvant treatment of postmenopausal women with hormone receptor positive early breast cancer ''(No change)'' | + | **Adjuvant treatment of postmenopausal women with [[Biomarkers#HR|hormone receptor]] [[Biomarkers#Expression|positive]] early [[breast cancer]]. ''(No change)'' |
| − | **Extended adjuvant treatment of postmenopausal women with early breast cancer who have received prior standard adjuvant tamoxifen therapy ''(Years requirement removed)'' | + | **Extended adjuvant treatment of postmenopausal women with early [[breast cancer]] who have received prior standard adjuvant tamoxifen therapy. ''(Years requirement removed)'' |
| − | **First and second-line treatment of postmenopausal women with hormone receptor positive or unknown advanced breast cancer | + | **First and second-line treatment of postmenopausal women with [[Biomarkers#HR|hormone receptor]] [[Biomarkers#Expression|positive]] or [[Biomarkers#Unknown|unknown]] advanced [[breast cancer]]. |
==Also known as== | ==Also known as== | ||
Revision as of 02:58, 15 January 2020
General information
Class/mechanism: Selective non-steroidal aromatase inhibitor. The aromatase enzyme converts adrenal and ovarian androgens (androstenedione and testosterone) to estrogens (estrone and estradiol) in peripheral tissues. Letrozole competitively binds to and inhibits the aromatase by binding to the heme of the enzyme's cytochrome P450.[1][2][3]
Route: PO
Extravasation: n/a
For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as Micromedex, Lexicomp, UpToDate (courtesy of Lexicomp), or the prescribing information.[1]
Diseases for which it is used
Patient drug information
- Letrozole (Femara) patient drug information (Chemocare)[4]
- Letrozole (Femara) patient drug information (UpToDate)[5]
History of changes in FDA indication
- 1/10/2001 (earliest label available at Drugs @ FDA): indicated for first-line treatment of postmenopausal women with hormone receptor positive or hormone receptor unknown locally advanced or metastatic breast cancer.
- Femara is also indicated for the treatment of advanced breast cancer in postmenopausal women with disease progression following antiestrogen therapy.
- 10/29/2004: Label expanded for the extended adjuvant treatment of early breast cancer in postmenopausal women who have received 5 years of adjuvant tamoxifen therapy. (Indication expanded to adjuvant setting after prior therapy)
- 12/28/2005: Label expanded for the adjuvant treatment of postmenopausal women with hormone receptor positive early breast cancer. (Indication expanded to adjuvant setting)
- 3/2/2010: Label simplified to:
- Adjuvant treatment of postmenopausal women with hormone receptor positive early breast cancer. (No change)
- Extended adjuvant treatment of postmenopausal women with early breast cancer who have received prior standard adjuvant tamoxifen therapy. (Years requirement removed)
- First and second-line treatment of postmenopausal women with hormone receptor positive or unknown advanced breast cancer.
Also known as
- Brand names: Femara, Fempro, Gynotril, Latrotal, Lerozol, Letoval, Letpro, Letromina, Letroplex, Letroz, Letrozol, Lexel, Lezole